



SPARC/Sec/SE/2022-23/116

March 24, 2023

To,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, 5th Floor, Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.

Scrip Symbol: SPARC

Dear Sir/Madam,

**Sub:** Clarification – Increase in Volume

**Ref:** Letter dated March 23, 2023 bearing reference no NSE/CM/Surveillance/12891

---

With reference to above referred letter, we confirm that the Company is in compliance with the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and that all the disclosures required to be made under the said regulation have been made to the exchanges. We are not aware of any information which qualifies to be disclosed under the said regulation but have not been disclosed.

We remain committed to make adequate and timely disclosures to the Stock Exchanges in compliance with the applicable regulations.

We request you to kindly take the same on record.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

**Chetan Rajpara**  
**Chief Financial Officer**

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.  
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India.